ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Vasculitis Guidelines in Focus, Part 4: Polyarteritis Nodosa

Michael Putman, MD  |  September 22, 2021

Jason Springer, MD, MS, served as one of the lead authors of the ACR/VF guidelines for polyarteritis nodosa (PAN), and talks about the recommendations specific to PAN here.

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:Guidelinespolyarteritis nodosaVasculitisVasculitis Foundation

Rituximab for Children with Lupus Nephritis

Lorraine L. Janeczko  |  September 15, 2021

NEW YORK (Reuters Health)—Pediatric rheumatologists and nephrologists appear to differ in their treatment choices for children who have lupus nephritis (LN), with rheumatologists more likely to prescribe rituximab, results of a small survey suggest. “This study highlights the importance of collaborative effort in developing CTPs (Consensus Treatment Plans) for pediatric LN,” the authors write in…

Filed under:Biologics/DMARDsConditionsSystemic Lupus Erythematosus Tagged with:Pediatrics

Vasculitis Guidelines in Focus, Part 3: EGPA

Michael Putman, MD  |  September 14, 2021

In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:AAV FocusRheumEGPAeosinophilic granulomatosis with polyangiitis (EGPA)guidelineVasculitis

Summer 2021’s Awards, Appointments & Announcements in Rheumatology

Kelly April Tyrrell & Gretchen Henkel  |  September 14, 2021

Marian Hannan Celebrated after 10 Years as AC&R Editor-in-Chief By Kelly April Tyrrell This summer, the 10-year tenure of Marian Hannan, MPH, DSc, as editor in chief of Arthritis Care & Research (AC&R), has come to an end. Kelli Allen, PhD, assumed the post on July 1. “Marian has done a fantastic job over the…

Filed under:AwardsProfiles Tagged with:Dr. John J. O’SheaDr. Marian HannanDr. Tuhina Neogi

Using Different Fibromyalgia Criteria Affects Prevalence Estimates

Deborah Levenson  |  September 14, 2021

A recent paper illustrates how using different fibromyalgia criteria affects reports of its prevalence.1 Writing in Arthritis Care & Research, researchers found the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks–American Pain Society Pain Taxonomy (AAPT) criteria caused far more people to be categorized as having fibromyalgia than criteria put forth by…

Filed under:ConditionsPain SyndromesSoft Tissue Pain Tagged with:Classification CriteriaFibromyalgia

COVID-19 & Pediatric Rheumatology

Elizabeth Sloan, MD  |  September 14, 2021

PRSYM 2021—Although primary COVID-19 infection has the most significant complications in adult patients, pediatric rheumatologists have also seen significant changes in their practice over the past year. With the emergence of COVID-19, the rise of a mysterious post-COVID hyper­inflammatory syndrome, now known as multisystem inflammatory syndrome in children (MIS-C), was identified, and pediatric rheumatologists have…

Filed under:ConditionsPediatric Conditions Tagged with:COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)PRSYM

Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis

Michael Putman, MD  |  September 9, 2021

Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:AAV FocusRheumANCA-Associated VasculitisguidelineVasculitisVasculitis Foundation

EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

Michele B. Kaufman, PharmD, BCGP  |  September 8, 2021

The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.

Filed under:ConditionsDrug UpdatesPediatric ConditionsPsoriatic Arthritis Tagged with:drug approvalsEuropeEuropean Unionjuvenile idiopathic arthritis (JIA)juvenile PsAPediatricPediatric RheumatologyPsApsoriatic arthritistofacitinib citrate

ACR Guidance on Tocilizumab Allocation During Shortage

From the College  |  September 1, 2021

In June, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab (Actemra) for treatment of hospitalized COVID-19 adults and children who are receiving systemic corticosteroids and supplemental oxygen. Since this announcement, the tocilizumab manufacturer, Genentech, has not been able to produce enough product to meet the higher demand. The…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:COVID-19Drug shortagetocilizumab

Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More

Elizabeth Sloan, MD  |  August 31, 2021

PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…

Filed under:ConditionsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:Lupus nephritisPediatricPediatric RheumatologyPRSYMsystemic lupus erythematosus (SLE)

  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 72
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences